Epidermal growth factor receptor expression has been demonstrated in 43–67% of patients with endometrial cancer and has similarly been associated with significantly shortened disease-free and overall survival (Khalifa et al, 1994; Scambia et al, 1994; Niikura et al, 1995). Here, EGFR is linked to endometrial cancer.